Search Medical Condition
Please enter condition
Please choose location

Germ Cell Tumors Clinical Trials

A listing of Germ Cell Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (17) clinical trials

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01602666?term=ACNS1123&rank=1

Phase N/A

Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

OBJECTIVES: Primary - Determine overall survival (OS) of patients with germ cell tumors treated with tandem autologous stem cell transplantation with non-cross-resistant conditioning regimens. Secondary - Determine disease-free survival (DFS) of patients treated with this regimen. - Determine the toxicity of tandem transplants - Determine the time to engraftment of ...

Phase

Treatment Outcome and Quality of Life in Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-1989-01

OBJECTIVES: - Determine the late effects of treatment and the quality-of-life of patients with germ cell tumors (GCT) previously treated on clinical trial CCLG-GC-1979-01 or CCLG-GC-1989-01. - Evaluate the late effects of carboplatin, etoposide, and bleomycin in patients treated on clinical trial CCLG-GC-1989-01. - Determine the toxicity of bleomycin and ...

Phase N/A

Gemcitabine Paclitaxel Ifosfamide and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors

OBJECTIVES: - To determine the maximum tolerated dose (MTD) of gemcitabine hydrochloride when administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin with growth factor support (Gem-TIP) in patients with progressive or relapsed metastatic germ cell tumors. - To compare the MTD of the Gem-TIP regimen with the MTD determined ...

Phase

Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy

Germ cell tumors, a relatively rare disease, but most common malignancy in young males, occur most frequently in testis. The incidence is about 1%, but is increasing in the majority of developed countries. The testicular cancer is an extremely important oncological condition due to his high rate of 80-90% of ...

Phase

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

OBJECTIVES: - Compare progression-free survival rates of patients with poor prognosis stage II or III non-seminomatous germ cell tumors with an unfavorable decrease of tumor markers after treatment with 1 course of bleomycin, etoposide, and cisplatin followed by subsequent treatment with 3 additional courses of bleomycin, etoposide, and cisplatin OR ...

Phase

Trial of Gemcitabine Cisplatin and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors

This is a prospective multicenter phase II trial of gemcitabine, cisplatin, and ifosfamide (GIP) in patients with relapsed non-seminomatous germ-cell tumors (NSGCT) and a predicted favorable prognosis.

Phase

Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors

Significant advances have been made in recent years in the treatment of solid tumors of childhood. However, much of the improvement in survival has been made in low stage and localized disease. Of significance is the fact that the improvements have come in up-front remission rates without translation into significantly ...

Phase

Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

Patients with metastatic germ cell cancer and relapse after two or more courses of cisplatin-based chemotherapy or after high-dose chemotherapy have a poor prognosis and no curative options. Taxanes in various combinations unfold cytotoxic effects on germ cell tumors resistant to conventional doses of cisplatin. Paclitaxel in combination with ifosfamide ...

Phase

A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors

Cabazitaxel is a new generation taxane with a high capacity for blood-brain barrier crossing and limited peripheral neuro-toxicity, two major potential advantages in patients with advanced NSGCTs. Cabazitaxel has a broader in vitro spectrum of activity than docetaxel. Taxanes have demonstrated activity in pre-treated GCTs and are now part of ...

Phase